Obvio Health USA, Inc.

Obvio Health USA, Inc. is a clinical trial technology company that focuses on providing innovative digital solutions to enhance the design and conduct of clinical trials for the pharmaceutical and biotechnology industries. Founded in 2015, Obvio Health USA, Inc. is based in Orlando, US.

The company specializes in offering a digital platform that enables efficient and accurate clinical trial management. The CEO, Ivan Jarry, leads the company, which has completed a total of 3 deals with a most recent funding round in July 2021. In this Series B funding round, Obvio Health raised USD 31. 00 mn from investors including AT Capital, Dedalus Spa, Novotech, and Sprim Ventures, which is the total amount raised to date.

ObvioHealth specializes in the provision of an advanced digital platform designed to enhance the efficiency and accuracy of clinical trials. Their core product, the ObvioGo® platform, streamlines study design and participant engagement while ensuring high data accuracy, effectively addressing the challenges of traditional clinical trial methodologies. The platform features various integrated tools, including the Study Designer, which allows users to create and customize clinical trials without coding, and the Study Manager, which centralizes trial management and ensures real-time compliance. These products primarily serve clients in the pharmaceutical and biotechnology sectors, facilitating decentralized clinical trials across various therapeutic areas.

ObvioHealth's solutions are utilized in multiple geographical markets, including North America, Europe, and Asia-Pacific, catering to a diverse client base that includes major pharmaceutical companies and clinical research organizations. ObvioHealth generates revenue through a subscription-based model, where clients, primarily in the life sciences sector, pay for access to the ObvioGo® platform and its associated services. Business transactions typically involve contracts for the use of their digital tools, where clients engage in annual or multi-year agreements that encompass various functionalities of the platform, such as electronic data capture (EDC), participant engagement tools, and analytics capabilities. These agreements facilitate a seamless process for managing clinical studies, enabling clients to optimize their study protocols and trial management.

The company’s revenue is bolstered by the provision of comprehensive support services, which can include training and consultation, enhancing the overall value delivered to clients through the use of their innovative digital solutions. Obvio Health USA, Inc. plans to utilize the USD 31. 00 mn raised in Series B funding to enhance the IT capabilities of its proprietary ecosystem for conducting virtual clinical trials and to expand its Singapore office into a technology hub.

The company is also focusing on the development of new products, designed to further streamline clinical trial processes, although specific launch dates have not been disclosed. In terms of geographic expansion, ObvioHealth aims to strengthen its presence in Asia-Pacific markets by the end of 2022.